{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:49:01Z","timestamp":1785466141340,"version":"3.56.0"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Bone health management in premenopausal women with breast cancer (BC) under hormone-deprivation therapies (HDTs) is often challenging, and the effectiveness of bone-active drugs is still unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective multicenter study included 306 premenopausal women with early BC undergoing HDTs. Bone mineral density (BMD) and morphometric vertebral fractures (VFs) were assessed 12 months after HDT initiation and then after at least 24 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After initial assessment, bone-active drugs were prescribed in 77.5% of women (151 denosumab 60 mg\/6 months, 86 bisphosphonates). After 47.0 \u00b1 20.1 months, new VFs were found in 16 women (5.2%). Vertebral fracture risk was significantly associated with obesity (odds ratio [OR] 3.87, P = .028), family history of hip fractures or VFs (OR 3.21, P = .040], chemotherapy-induced menopause (OR 6.48, P &amp;lt; .001), preexisting VFs (OR 25.36, P &amp;lt; .001), baseline T-score less than or equal to \u22122.5 standard deviation (SD) at any skeletal site (OR 4.14, P = .036), and changes at lumbar and total hip BMD (OR 0.94, P = .038 and OR 0.88, P &amp;lt; .001, respectively). New VFs occurred more frequently in women untreated compared to those treated with bone-active drugs (14\/69, 20.8% vs 2\/237, 0.8%; P &amp;lt; .001) and the anti-fracture effectiveness remained significant after correction for BMI (OR 0.03; P &amp;lt; .001), family history of fractures (OR 0.03; P &amp;lt; .001), chemotherapy-induced menopause (OR 0.04; P &amp;lt; .001), and preexisting VFs (OR 0.01; P &amp;lt; .001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Premenopausal women under HDTs are at high risk of VFs in relationship with high BMI, densitometric diagnosis of osteoporosis, preexisting VFs, and family history of osteoporotic fractures. Vertebral fractures in this setting might be effectively prevented by bisphosphonates or denosumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvae086","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T16:16:48Z","timestamp":1721924208000},"page":"117-125","source":"Crossref","is-referenced-by-count":10,"title":["Bone-active drugs in premenopausal women with breast cancer under hormone-deprivation therapies"],"prefix":"10.1093","volume":"191","author":[{"given":"Maria Francesca","family":"Birtolo","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Pedersini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-4926","authenticated-orcid":false,"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]},{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Vena","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Diabetology and Endocrinology, Humanitas Gavazzeni , 24125 Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Morenghi","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Biostatistics Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Cristofolini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Presciuttini","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Medicine, ASST Carlo Poma , 46100 Mantua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0700","authenticated-orcid":false,"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda Mihaela","family":"Naciu","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Pigni","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Mazzoleni","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antea","family":"Ciafardini","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pagani","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Medicine, ASST Carlo Poma , 46100 Mantua ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Radiology, University of Brescia, ASST Spedali Civili , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Balzarini","sequence":"additional","affiliation":[{"name":"Department of Radiology, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zambelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Cancer Center, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalba","family":"Torrisi","sequence":"additional","affiliation":[{"name":"Cancer Center, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Cianferotti","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Biomedical Sciences \u201cMario Serio\u201d, University of Florence , 50134 Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3091-8205","authenticated-orcid":false,"given":"Nicola","family":"Napoli","sequence":"additional","affiliation":[{"name":"Unit of Metabolic Bone and Thyroid Diseases, Fondazione Policlinico Universitario Campus Bio-Medico , 00128 Rome ,","place":["Italy"]},{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma , 00128 Rome ,","place":["Italy"]},{"name":"Division of Bone and Mineral Diseases, Washington University in St Louis , St Louis, MO 63130 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Carlo","family":"Bossi","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma , 00128 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-2141","authenticated-orcid":false,"given":"Andrea Gerardo","family":"Lania","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3956-0043","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, Medical Oncology, University of Brescia, ASST Spedali Civili , 25123 Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5458-701X","authenticated-orcid":false,"given":"Gherardo","family":"Mazziotti","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Humanitas University , 20090 Pieve Emanuele-Milan ,","place":["Italy"]},{"name":"Endocrinology, Diabetology and Medical Andrology Unit, IRCCS Humanitas Research Hospital , 20089 Rozzano-Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"issue":"3","key":"2024112512433162200_lvae086-B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2024112512433162200_lvae086-B2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2024112512433162200_lvae086-B3","first-page":"CD013538","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"2024112512433162200_lvae086-B4","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials","volume":"23","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024112512433162200_lvae086-B5","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"7","key":"2024112512433162200_lvae086-B6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"issue":"2","key":"2024112512433162200_lvae086-B7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"issue":"2","key":"2024112512433162200_lvae086-B8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2024112512433162200_lvae086-B9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"2024112512433162200_lvae086-B10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur J Cancer"},{"issue":"11","key":"2024112512433162200_lvae086-B11","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00198-018-4642-2","article-title":"The tamoxifen paradox-influence of adjuvant tamoxifen on fracture risk in pre- and postmenopausal women with breast cancer","volume":"29","author":"Kyvernitakis","year":"2018","journal-title":"Osteoporos Int"},{"key":"2024112512433162200_lvae086-B12","first-page":"163","article-title":"Cancer treatment-induced bone loss: role of denosumab in non-metastatic breast cancer","volume":"14","author":"Dhabhar","year":"2022","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2024112512433162200_lvae086-B13","doi-asserted-by":"crossref","first-page":"100355","DOI":"10.1016\/j.jbo.2021.100355","article-title":"Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer","volume":"28","author":"Waqas","year":"2021","journal-title":"J Bone Oncol"},{"issue":"2","key":"2024112512433162200_lvae086-B14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","article-title":"Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989","volume":"7","author":"Cooper","year":"1992","journal-title":"J Bone Miner Res"},{"issue":"9596","key":"2024112512433162200_lvae086-B15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"2024112512433162200_lvae086-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/reumatismo.2016.870","article-title":"Guidelines for the diagnosis, prevention and management of osteoporosis","volume":"68","author":"Rossini","year":"2016","journal-title":"Reumatismo"},{"issue":"18","key":"2024112512433162200_lvae086-B17","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","article-title":"Interrupting endocrine therapy to attempt pregnancy after breast cancer","volume":"388","author":"Partridge","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"2024112512433162200_lvae086-B18","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/s00228-024-03693-7","article-title":"Does the use of bisphosphonates during pregnancy affect fetal outcomes? A systematic review","volume":"80","author":"de Campos","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2024112512433162200_lvae086-B19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00198-018-4793-1","article-title":"Vertebral fractures cascade: potential causes and risk factors","volume":"30","author":"Che","year":"2019","journal-title":"Osteoporos Int"},{"issue":"10","key":"2024112512433162200_lvae086-B20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.amjmed.2010.02.028","article-title":"Drug-induced osteoporosis: mechanisms and clinical implications","volume":"123","author":"Mazziotti","year":"2010","journal-title":"Am J Med"},{"issue":"1","key":"2024112512433162200_lvae086-B21","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/jbmr.533","article-title":"Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence","volume":"27","author":"Sampalis","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024112512433162200_lvae086-B22","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00198-016-3886-y","article-title":"Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years","volume":"28","author":"Modi","year":"2017","journal-title":"Osteoporos Int"},{"issue":"3","key":"2024112512433162200_lvae086-B23","doi-asserted-by":"crossref","first-page":"165","DOI":"10.23736\/S0391-1977.20.03137-5","article-title":"Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab","volume":"45","author":"Betella","year":"2020","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"2024112512433162200_lvae086-B24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00198-013-2567-3","article-title":"Vertebral fracture assessment (VFA) by lateral DXA scanning may be cost-effective when used as part of fracture liaison services or primary care screening","volume":"25","author":"Clark","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024112512433162200_lvae086-B25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12020-012-9691-2","article-title":"New advances in imaging osteoporosis and its complications","volume":"42","author":"Griffith","year":"2012","journal-title":"Endocrine"},{"issue":"10","key":"2024112512433162200_lvae086-B26","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1007\/s40618-022-01837-z","article-title":"Artificial intelligence-based radiomics on computed tomography of lumbar spine in subjects with fragility vertebral fractures","volume":"45","author":"Biamonte","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2024112512433162200_lvae086-B27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11657-019-0577-2","article-title":"Automated quantitative morphometry of vertebral heights on spinal radiographs: comparison of a clinical workflow tool with standard 6-point morphometry","volume":"14","author":"Engelke","year":"2019","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2024112512433162200_lvae086-B28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bone.2005.04.003","article-title":"Prognostic utility of a semiquantitative spinal deformity index","volume":"37","author":"Crans","year":"2005","journal-title":"Bone"},{"issue":"4","key":"2024112512433162200_lvae086-B29","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jocd.2013.08.004","article-title":"Executive summary of the 2013 International Society for Clinical Densitometry Position Development Conference on bone densitometry","volume":"16","author":"Schousboe","year":"2013","journal-title":"J Clin Densitom"},{"issue":"9","key":"2024112512433162200_lvae086-B30","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"18","key":"2024112512433162200_lvae086-B31","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","article-title":"Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy","volume":"22","author":"Sverrisdottir","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024112512433162200_lvae086-B32","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1200\/JCO.1996.14.1.78","article-title":"Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women","volume":"14","author":"Powles","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024112512433162200_lvae086-B33","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00198-003-1508-y","article-title":"Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)","volume":"14","author":"Fogelman","year":"2003","journal-title":"Osteoporos Int"},{"issue":"1","key":"2024112512433162200_lvae086-B34","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00198-014-2955-3","article-title":"Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy","volume":"26","author":"Kalder","year":"2015","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024112512433162200_lvae086-B35","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s40618-019-01063-0","article-title":"Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors","volume":"42","author":"Catalano","year":"2019","journal-title":"J Endocrinol Invest"},{"issue":"7","key":"2024112512433162200_lvae086-B36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"issue":"11","key":"2024112512433162200_lvae086-B37","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.3390\/jcm8111894","article-title":"Bone health management in patients with early breast cancer: a retrospective Italian Osteoncology Center \u201cReal-Life\u201d experience (BOHEME study)","volume":"8","author":"Recine","year":"2019","journal-title":"J Clin Med"},{"key":"2024112512433162200_lvae086-B38","doi-asserted-by":"crossref","first-page":"100254","DOI":"10.1016\/j.jbo.2019.100254","article-title":"Incidence of fractures in young women with breast cancer\u2014a retrospective cohort study","volume":"18","author":"Stumpf","year":"2019","journal-title":"J Bone Oncol"},{"issue":"1","key":"2024112512433162200_lvae086-B39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13643-023-02181-w","article-title":"Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools","volume":"12","author":"Gates","year":"2023","journal-title":"Syst Rev"},{"issue":"5","key":"2024112512433162200_lvae086-B40","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/jbmr.4250","article-title":"Bone mineral density at the time of initiating aromatase inhibitor therapy is associated with decreased fractures in women with breast cancer","volume":"36","author":"Lu","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"10","key":"2024112512433162200_lvae086-B41","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1002\/jbmr.4108","article-title":"Grade 1 vertebral fractures identified by densitometric lateral spine imaging predict incident major osteoporotic fracture independently of clinical risk factors and bone mineral density in older women","volume":"35","author":"Johansson","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2024112512433162200_lvae086-B42","doi-asserted-by":"crossref","first-page":"100421","DOI":"10.1016\/j.jbo.2022.100421","article-title":"Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice","volume":"33","author":"Mazziotti","year":"2022","journal-title":"J Bone Oncol"},{"issue":"5","key":"2024112512433162200_lvae086-B43","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s00223-022-01011-w","article-title":"Real-world effectiveness of denosumab and bisphosphonates on risk of vertebral fractures in women with breast cancer undergoing treatment with aromatase inhibitors","volume":"111","author":"Mazziotti","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"2024112512433162200_lvae086-B44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.bone.2017.01.013","article-title":"Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: a cross-sectional study","volume":"97","author":"Pedersini","year":"2017","journal-title":"Bone"},{"issue":"2","key":"2024112512433162200_lvae086-B45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/os.13184","article-title":"Relationship between change in bone mineral density of lumbar spine and risk of new vertebral and nonvertebral fractures: a meta-analysis","volume":"14","author":"Chen","year":"2022","journal-title":"Orthop Surg"},{"issue":"4","key":"2024112512433162200_lvae086-B46","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"31","key":"2024112512433162200_lvae086-B47","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.01696","article-title":"Management of osteoporosis in survivors of adult cancers with nonmetastatic disease: ASCO clinical practice guideline","volume":"37","author":"Shapiro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"11","key":"2024112512433162200_lvae086-B48","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","article-title":"Body mass index as a predictor of fracture risk: a meta-analysis","volume":"16","author":"De Laet","year":"2005","journal-title":"Osteoporos Int"},{"issue":"9","key":"2024112512433162200_lvae086-B49","doi-asserted-by":"crossref","first-page":"e1911080","DOI":"10.1001\/jamanetworkopen.2019.11080","article-title":"Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy","volume":"2","author":"Pedersini","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2024112512433162200_lvae086-B50","doi-asserted-by":"crossref","first-page":"e10440","DOI":"10.1002\/jbm4.10440","article-title":"The interaction of lean body mass with fat body mass is associated with vertebral fracture prevalence in women with early breast cancer undergoing aromatase inhibitor therapy","volume":"5","author":"Monteverdi","year":"2021","journal-title":"JBMR Plus"},{"issue":"10","key":"2024112512433162200_lvae086-B51","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s11912-023-01447-9","article-title":"Role of body composition in the prediction of skeletal fragility induced by hormone deprivation therapies in cancer patients","volume":"25","author":"Dalla Volta","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"2024112512433162200_lvae086-B52","doi-asserted-by":"crossref","first-page":"e2350950","DOI":"10.1001\/jamanetworkopen.2023.50950","article-title":"Fat body mass and vertebral fracture progression in women with breast cancer","volume":"7","author":"Cosentini","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2024112512433162200_lvae086-B53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbo.2017.03.001","article-title":"Management of aromatase inhibitor-associated bone loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG","volume":"7","author":"Hadji","year":"2017","journal-title":"J Bone Oncol"},{"issue":"9","key":"2024112512433162200_lvae086-B54","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2024112512433162200_lvae086-B55","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7","key":"2024112512433162200_lvae086-B56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","article-title":"Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer","volume":"27","author":"Hines","year":"2009","journal-title":"J Clin Oncol"},{"key":"2024112512433162200_lvae086-B57","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2018.02.004","article-title":"Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01\/04) study","volume":"94","author":"Wilson","year":"2018","journal-title":"Eur J Cancer"},{"issue":"2","key":"2024112512433162200_lvae086-B58","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.breast.2014.12.008","article-title":"Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer","volume":"24","author":"Koopal","year":"2015","journal-title":"Breast"},{"issue":"1","key":"2024112512433162200_lvae086-B59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12875-018-0828-0","article-title":"Factors related to intentional non-initiation of bisphosphonate treatment in patients with a high fracture risk in primary care: a qualitative study","volume":"19","author":"Swart","year":"2018","journal-title":"BMC Fam Pract"},{"issue":"11","key":"2024112512433162200_lvae086-B60","doi-asserted-by":"crossref","first-page":"e040634","DOI":"10.1136\/bmjopen-2020-040634","article-title":"Acceptability of bisphosphonates among patients, clinicians and managers: a systematic review and framework synthesis","volume":"10","author":"Paskins","year":"2020","journal-title":"BMJ Open"},{"key":"2024112512433162200_lvae086-B61","first-page":"dgae003","article-title":"Cardiometabolic effects of denosumab in premenopausal women with breast cancer receiving estradiol suppression: RCT","author":"Ramchand","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024112512433162200_lvae086-B62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00223-012-9643-0","article-title":"Diagnostic performance of vertebral fracture assessment by the lunar iDXA scanner compared to conventional radiography","volume":"91","author":"Diacinti","year":"2012","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"2024112512433162200_lvae086-B63","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40618-023-02174-5","article-title":"Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors","volume":"47","author":"Antonini","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2024112512433162200_lvae086-B64","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvae086\/58656038\/lvae086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/2\/117\/60808140\/lvae086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/191\/2\/117\/60808140\/lvae086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:43:53Z","timestamp":1732538633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/191\/2\/117\/7721230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvae086","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,26]]}}}